Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice

Free Radical Biology and Medicine

Volumn 60, Issue , 2013, Pages 307-317

  Huynh, Karina ^a,b   Kiriazis, Helen ^a   Du, Xiao Jun ^a   Love, Jane E ^a   Gray, Stephen P ^a   Jandeleit Dahm, Karin A ^a   McMullen, Julie R ^a,b,c   Ritchie, Rebecca H ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Apoptosis; Cardiomyocyte; Coenzyme Q10; Diabetes; Diastolic function; Fibrosis; Free radicals; Hypertrophy; Inflammation; Superoxide

Indexed keywords

3 NITROTYROSINE; CITRIC ACID; OLIVE OIL; PROTEIN P22; PROTEIN P47; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STREPTOZOCIN; SUPEROXIDE; UBIDECARENONE; UNCOUPLING PROTEIN 3;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DECELERATION; DIABETIC CARDIOMYOPATHY; GLYCEMIC CONTROL; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HYPERGLYCEMIA; HYPERTROPHY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPLEMENTATION;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC CARDIOMYOPATHIES; HUMANS; HYPERGLYCEMIA; LIPID PEROXIDATION; MALE; MICE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; UBIQUINONE; UP-REGULATION; VENTRICULAR REMODELING;

MUS;

EID: 84875987345     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2013.02.021     Document Type: Article

References (60)

1. J.E. Shaw, R.A. Sicree, and P.Z. Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Res. Clin. Pract. 87 2010 4 14
2. L.S. Geiss, W.H. Herman, P.J. Smith, and National Diabetes Data Group Diabetes in America, 2nd edition, NIH Publication No. 95-1468 1995 NIDDK, NIH Bethesda 233-257
3. T. Nishikawa, D. Edelstein, X.L. Du, S. Yamagishi, T. Matsumura, Y. Kaneda, M.A. Yorek, D. Beebe, P.J. Oates, H.P. Hammes, I. Giardino, and M. Brownlee Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 2000 787 790
4. 10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes Free Radic. Biol. Med. 52 2012 716 723
5. M.A. Haidara, H.Z. Yaseen, M. Rateb, H. Ammar, and M.A. Zorkani Role of oxidative stress in development of cardiovascular complications in diabetes mellitus Curr. Vasc. Pharmacol. 4 2006 215 227
6. L.E. Wold, A.F. Ceylan-Isik, and J. Ren Oxidative stress and stress signaling: menace of diabetic cardiomyopathy Acta Pharmacol. Sin. 26 2005 908 917
7. J.L. Evans, I.D. Goldfine, B.A. Maddux, and G.M. Grodsky Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52 2003 1 8
8. A.C. Maritim, R.A. Sanders, and J.B. Watkins Diabetes, oxidative stress, and antioxidants: a review J. Biochem. Mol. Toxicol. 17 2003 24 38
9. M Hamblin, D.B. Friedman, S. Hill, R.M. Caprioli, H.M. Smith, and M.F. Hill Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy J. Mol. Cell. Cardiol. 42 2007 884 895
10. G.R. Drummond, S. Selemidis, K.K. Griendling, and C.G. Sobey Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets Nat. Rev. Drug Discovery 10 2011 453 471
11. M. Seddon, Y.H. Looi, and A.M. Shah Oxidative stress and redox signalling in cardiac hypertrophy and heart failure Heart 93 2007 903 907
12. S. Dikalov Cross talk between mitochondria and NADPH oxidases Free Radic. Biol. Med. 51 2011 1289 1301
13. A.K. Doughan, D.G. Harrison, and S.I. Dikalov Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction Circ. Res. 102 2008 488 496
14. J.M. Li, N.P. Gall, D.J. Grieve, M.Y. Chen, and A.M. Shah Activation of NADPH oxidase during progression of cardiac hypertrophy to failure Hypertension 40 2002 477 484
15. A. Schramm, P. Matusik, G. Osmenda, and T.J. Guzik Targeting NADPH oxidases in vascular pharmacology Vasc. Pharmacol. 56 2012 216 231
16. R.H. Ritchie, J.C. Irvine, A.C. Rosenkranz, R. Patel, I.R. Wendt, J.D. Horowitz, and B.K. Kemp-Harper Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO and beyond Pharmacol. Ther. 124 2009 279 300
17. M. Bentinger, K. Brismar, and G. Dallner The antioxidant role of coenzyme Q Mitochondrion 7 2007 S41 S50
18. 10 as a front-line antioxidant against oxidative stress J. Clin. Biochem. Nutr. 36 2005 29 35
19. 10 illuminated by meta-analyses of clinical trials Mol. Aspects Med 18 1997 S159 S168
20. 10 in cardiovascular disease BioFactors 9 1999 273 284
21. 10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes Diabetologia 55 2012 1544 1553
22. M. Galderisi, K.M. Anderson, P.W.F. Wilson, and D. Levy Echocardiography evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham-Heart Study) Am. J. Cardiol. 68 1991 85 89
23. S. Rubler, Y.Z. Yuceoglu, T. Kumral, A. Grishman, A.W. Branwood, and J. Dlugash New type of cardiomyopathy associated with diabetic glomerulosclerosis Am. J. Cardiol. 30 1972 595 602
24. S. Boudina, and E.D. Abel Diabetic cardiomyopathy, causes and effects Rev. Endocr. Metab. Disord. 11 2010 31 39
25. C.M. Schannwell, M. Schneppenheim, S. Perings, G. Plehn, and B.E. Strauer Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy Cardiology 98 2002 33 39
26. K.C. Chang, C.D. Tseng, T.F. Chou, Y.L. Cho, T.C. Chi, M.J. Su, and Y.Z. Tseng Arterial stiffening and cardiac hypertrophy in a new rat model of type 2 diabetes Eur. J. Clin. Invest. 36 2006 1 7
27. J. Asbun, and F.J. Villarreal The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy J. Am. Coll. Cardiol. 47 2006 693 700
28. L. Cai, W. Li, G.W. Wang, L.P. Guo, Y.C. Jiang, and Y.J. Kang Hyperglycaemia-induced apoptosis in mouse myocardium - mitochondrial cytochrome c-mediated caspase-3 activation pathway Diabetes 51 2002 1938 1948
29. S.P. Laing, A.J. Swerdlow, S.D. Slater, J.L. Botha, A.C. Burden, N.R. Waugh, A.W. Smith, R.D. Hill, P.J. Bingley, C.C. Patterson, Z. Qiao, and H. Keen The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus Diabetic Med. 16 1999 466 471
30. T.A. Aksnes, S.E. Kjeldsen, M. Rostrup, P. Omvik, T.A. Hua, and S. Julius Impact of new-onset diabetes mellitus on cardiac outcomes in the VALUE trial population Hypertension 50 2007 467 573
31. R.E. Gilbert, K. Connelly, D.J. Kelly, C.A. Pollock, and H. Krum Heart failure and nephropathy: catastrophic and interrelated complications of diabetes Clin. J. Am. Soc. Nephrol. 1 2006 193 208
32. C. Berry, J.C. Tardif, and M.G. Bourassa Coronary heart disease in patients with diabetes. Part I. Recent advances in prevention and noninvasive management J. Am. Coll. Cardiol. 49 2007 631 642
33. J.M. Neutel Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy Curr. Med. Res. Opin 26 2010 213 222
34. 10 Diabetic Med. 23 2006 1344 1349
35. K. Huynh, J.R. McMullen, T. Julius, J.W. Tan, J.E. Love, N. Cemerlang, H. Kiriazis, X.J. Du, and R.H. Ritchie Cardiac-specific insulin-like growth factor 1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy Diabetes 59 2010 1512 1520
36. R.H. Ritchie, J.E. Love, K. Huynh, B.C. Bernardo, D.C. Henstridge, H. Kiriazis, Y.K. Tham, G. Sapra, C.X. Qin, N. Cemerlang, E.J. Boey, K.A. Jandeleit-Dahm, X.J Du, and J.R. McMullen Enhanced phosphoinositide 3-kinase (p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes Diabetologia 55 2012 3369 3381
37. H. Bugger, and E.D Abel Rodent models of diabetic cardiomyopathy Dis. Models Mech 2 2009 454 466
38. A.M.D. Watson, A. Soro-Paavonen, K. Sheehy, J. Li, A.C. Calkin, A. Koitka, S.N. Rajan, D. Brasacchio, T.J. Allen, M.E. Cooper, M.C. Thomas, and K.J. Jandeleit-Dahm Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice Diabetologia 54 2011 681 689
39. R.H. Ritchie, J.M. Quinn, A.H. Cao, G.R. Drummond, D.M. Kaye, J.M. Favaloro, J. Proietto, and L.M.D. Delbridge The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo J. Mol. Cell. Cardiol. 42 2007 1119 1128
40. 10 Mol. Aspects Med 18 Suppl 1997 S145 S151
41. 10 in myocardial failure Drugs Exp. Clin. Res. 10 1984 497 502
42. 10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease Nutrition 28 2012 767 772
43. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
44. S. Boudina, S. Sena, C. Sloan, A. Tebbi, Y.H. Han, B.T. O'Neill, R.C. Cooksey, D. Jones, W.L. Holland, D.A. McClain, and E.D. Abel Early mitochondrial adaptations in skeletal muscle to diet-induced obesity are strain dependent and determine oxidative stress and energy expenditure but not insulin sensitivity Endocrinology 153 2012 2677 2688
45. G. Poli, and M. Parola Oxidative damage and fibrogenesis Free Radic. Biol. Med. 22 1997 287 305
46. 2-adrenoceptor activation-induced cardiomyopathy and heart failure Br. J. Pharmacol. 162 2011 1012 1028
47. S.P. Levick, J.L. McLarty, D.B. Murray, R.M. Freeman, W.E. Carver, and G.L. Brower Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart Hypertension 53 2009 1041 1047
48. S.A. Cooper, A. Whaley-Connell, J. Habibi, Y.Z. Wei, G. Lastra, C. Manrique, S. Stas, and J.R. Sowers Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance Am. J. Physiol. Heart Circ. Physiol 293 2007 H2009 H2023
49. P. Ruggenenti, I. Iliev, G.M. Costa, A. Parvanova, A. Perna, G.A. Giuliano, N. Motterlini, B. Ene-Iordache, and G. Remuzzi Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Diabetes Care 31 2008 1629 1634
50. B.C. Bernardo, K.L. Weeks, L. Pretorius, and J.R. McMullen Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies Pharmacol. Ther. 128 2010 191 227
51. G. Bajraktari, M.S. Koltai, F. Ademaj, N. Rexhepaj, S. Qirko, G. Ndrepepa, and S. Elezi Relationship between insulin resistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes Int. J. Cardiol. 110 2006 206 211
52. T.E. Owan, D.O. Hodge, R.M. Herges, S.J. Jacobsen, V.L. Roger, and M.M. Redfield Trends in prevalence and outcome of heart failure with preserved ejection fraction N. Engl. J. Med. 355 2006 251 259
53. B. Shivalkar, D. Dhondt, I. Goovaerts, L. Van Gaal, J. Bartunek, P. Van Crombrugge, and C. Vrints Flow mediated dilatation and cardiac function in type 1 diabetes mellitus Am. J. Cardiol. 97 2006 77 82
54. A. Daniels, M. van Bilsen, R. Goldschmeding, G.J van der Vusse, and F.A. van Nieuwenhoven Connective tissue growth factor and cardiac fibrosis Acta Physiol. 195 2009 321 338
55. 10 BioFactors 32 2008 199 208
56. 10 (ubiquinone) Regul. Toxicol. Pharmacol. 45 2006 282 288
57. K.L. Ferrante, J. Shefner, H. Zhang, R. Betensky, M. O'Brien, H. Yu, M. Fantasia, J. Taft, M.F. Beal, B. Traynor, K. Newhall, P. Donofrio, J. Caress, C. Ashburn, B. Freiberg, C. O'Neill, C. Paladenech, T. Walker, A. Pestronk, B. Abrams, J. Florence, R. Renna, J. Schierbecker, B. Malkus, and M Cudkowicz Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS Neurology 65 2005 1834 1836
58. 10 in Huntington's disease and healthy subjects Mov. Disord 25 2010 1924 1928
59. F. Rosenfeldt, D. Hilton, S. Pepe, and H. Krum Systematic review of effect of coenzyme Q(10) in physical exercise, hypertension and heart failure BioFactors 18 2003 91 100
60. M.A. Silver, P.H. Langsjoen, S. Szabo, H. Patil, and A. Zelinger Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q(10) to reverse that dysfunction Am. J. Cardiol. 94 2004 1306 1310